argenx SE announced the appointment of Wim Parys M.D. as Chief Medical Officer effective July 1, 2019. Dr. Parys will succeed outgoing Chief Medical Officer Nicolas Leupin, M.D. who will be departing from the Company. In his role, Dr. Parys will lead argenx’s clinical development, clinical operations, regulatory affairs, pharmacovigilance and project management. Dr. Parys has served as an R&D consultant to argenx since February 2019. Dr. Parys held several R&D leadership roles of increasing responsibility at Janssen, J&J and Tibotec, including Head of Development at Tibotec where he established and led Tibotec Inc.